BioSpace News Archive

LivaNova PLC, a market-leading medical technology company, announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at the Piper Sandler Healthcare Conference in New York.

Masimo announced that its management will participate in the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 3:00 pm GMT.

Bristol Myers Squibb announced that the U.S. Food and Drug Administration has accepted the supplemental Biologics License Application for Breyanzi to expand its current indication to include the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received a prior Bruton tyrosine kinase inhibitor and B-cell lymphoma 2 inhibitor.

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has received the permanent Manufacturer’s Authorization for its clinical development site in Rankweil, Austria.

Alladapt Immunotherapeutics, Inc. announced that data from the Phase 1/2 Harmony study will be presented at the 2023 Annual Scientific Meeting of the American College of Asthma, Allergy and Immunology taking place Nov. 9-13.

As a pioneer in innovative chaperone technology, SOLA Biosciences Inc. will present its compelling preclinical proof-of-concept data for SOL-257, a targeted gene therapy for misfolded TDP-43 in Amyotrophic Lateral Sclerosis, at Neuroscience 2023 in Washington, D.C. on November 15 and the ALS One Symposium on November 17.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company”), announces that it has granted a total of 6,250,000 stock options (“Options”) to purchase common shares of the Company to certain officers,

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced its third quarter 2023 financial results and is providing an update on its plans to advance clinical development of KIO-301 for other inherited retinal diseases.

Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness,

Entera Bio Ltd. reports that the American Society for Bone and Mineral Research has announced that the SABRE project team has submitted to the U.S. Food and Drug Administration its full qualification plan to use the treatment-related change in bone mineral density as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs.